Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effects of Rhodiola Rosea Supplementation on Anaerobic Performance and Blood Lactate in Trained Men

9 novembre 2026 aggiornato da: Yucel Makaraci, Karamanoğlu Mehmetbey University

Effects of Short-term Rhodiola Rosea Supplementation on Anaerobic Performance and Serial Post-exercise Blood Lactate Responses in Trained Men: A Randomized, Double-blind, Placebo-controlled Crossover Trial

This study aimed to investigate the effects of short-term Rhodiola rosea supplementation on anaerobic exercise performance and blood lactate responses during post-exercise recovery in trained male athletes.

The study used a randomized, double-blind, placebo-controlled crossover design involving 23 trained men. Each participant completed two experimental conditions: Rhodiola rosea supplementation and placebo, administered in a randomized order with a 5-day washout period between conditions.

During the Rhodiola rosea condition, participants received 1,500 mg per day for three consecutive days, followed by an additional 500 mg dose 30 minutes before exercise testing. The placebo condition followed an identical administration schedule without the active supplement.

Following each supplementation condition, participants performed a 30-second Wingate Anaerobic Test to assess anaerobic performance. Blood lactate concentrations were measured before exercise and at 3, 10, and 20 minutes after exercise.

The study was designed to determine whether short-term Rhodiola rosea supplementation influences maximal anaerobic performance and blood lactate concentrations during recovery from high-intensity exercise.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Rhodiola rosea is a plant-derived supplement containing bioactive compounds, including rosavins and salidroside, that have been investigated for their potential effects on physical performance, fatigue, and exercise-related physiological responses. Although previous research has examined the effects of Rhodiola rosea on different exercise modalities, evidence regarding its influence on anaerobic performance and serial blood lactate responses following a single bout of high-intensity exercise remains limited.

This study investigated whether short-term Rhodiola rosea supplementation affects performance during a 30-second Wingate Anaerobic Test (WAnT-30) and blood lactate concentrations during subsequent recovery.

The study employed a randomized, double-blind, placebo-controlled crossover design. Twenty-three trained male athletes completed both supplementation conditions in a randomized sequence. Participants received either Rhodiola rosea or placebo during the first experimental period and the alternate condition during the second period. A 5-day supplement-free washout interval separated the two supplementation periods.

The Rhodiola rosea supplementation protocol consisted of 1,500 mg daily for three consecutive days, administered in three separate 500 mg doses, followed by an additional 500 mg dose 30 minutes before the exercise test. The placebo consisted of an identically flavored non-caloric beverage without active supplementation. Both preparations were administered under standardized conditions to maintain blinding.

Following each supplementation period, participants completed a standardized warm-up and performed a maximal 30-second Wingate test using a cycle ergometer. Anaerobic performance variables included peak power, relative peak power, mean power, total work, cadence at peak power, and rate of fatigue.

Capillary blood lactate concentrations were assessed at rest and at 3, 10, and 20 minutes following the Wingate test. Participants remained seated throughout the post-exercise recovery period.

Dietary intake, physical activity, caffeine consumption, and testing conditions were standardized as far as possible to minimize potential confounding effects.

The study was designed to evaluate the effects of short-term Rhodiola rosea supplementation on maximal anaerobic performance and post-exercise blood lactate responses compared with placebo.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

23

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Karaman
      • Karaman, Karaman, Turchia (Türkiye), 70200
        • Faculty of Sports Sciences Exercise Physiology Laboratory

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 24 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion Criteria:

  • Healthy male athletes aged 18 years or older.
  • Regular participation in sport-specific training at least three times per week.
  • Active participation in organized competitive sports.
  • Engagement in structured training aimed at improving athletic performance.
  • Regular participation in lower-body resistance training as part of habitual training programs.
  • Previous experience with submaximal exercise testing on a cycle ergometer.
  • No musculoskeletal injuries or medical conditions that could affect exercise performance.
  • Maintenance of regular training during the month preceding the study.
  • Voluntary participation and provision of written informed consent.

Exclusion Criteria:

  • Previous use of Rhodiola rosea supplementation.
  • Use of any ergogenic supplements within one week before the beginning of the study or during the experimental period.
  • History of lower-limb surgery within the previous 12 months.
  • Presence of musculoskeletal injuries or medical conditions that could interfere with exercise performance.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Rhodiola rosea Followed by Placebo

Subjects assigned to this sequence received Rhodiola rosea supplementation during the first experimental period, followed by placebo during the second period. Rhodiola rosea was administered at 1,500 mg/day for three consecutive days, with an additional 500 mg dose 30 minutes before the Wingate test. A 5-day supplement-free washout period separated the two experimental periods. Twelve subjects completed this sequence.

Rhodiola rosea extract (Solgar Rhodiola Root Extract, Solgar Inc., USA), standardized to 3% rosavins and 1% salidroside, was administered at 1,500 mg/day for three consecutive days (500 mg three times daily), followed by an additional 500 mg dose 30 minutes before the Wingate Anaerobic Test. The total dose was 5,000 mg per experimental period. The supplement was administered in a non-caloric mango-flavored beverage.

The placebo consisted of an identical non-caloric mango-flavored beverage without Rhodiola rosea extract or any other active supplement. It was administered according to the same schedule as the active supplementation condition to maintain blinding.

Sperimentale: Placebo Followed by Rhodiola rosea

Subjects assigned to this sequence received placebo during the first experimental period, followed by Rhodiola rosea supplementation during the second period. The placebo followed the same administration schedule as the active supplementation condition but contained no Rhodiola rosea extract. A 5-day supplement-free washout period separated the two experimental periods. Eleven subjects completed this sequence.

Rhodiola rosea extract (Solgar Rhodiola Root Extract, Solgar Inc., USA), standardized to 3% rosavins and 1% salidroside, was administered at 1,500 mg/day for three consecutive days (500 mg three times daily), followed by an additional 500 mg dose 30 minutes before the Wingate Anaerobic Test. The total dose was 5,000 mg per experimental period. The supplement was administered in a non-caloric mango-flavored beverage.

The placebo consisted of an identical non-caloric mango-flavored beverage without Rhodiola rosea extract or any other active supplement. It was administered according to the same schedule as the active supplementation condition to maintain blinding.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Peak Power During the 30-Second Wingate Anaerobic Test
Lasso di tempo: During the 30-second Wingate test at the end of each 4-day supplementation period

Peak power (W) was measured during the 30-second Wingate Anaerobic Test using a cycle ergometer (Lode Excalibur Sport). The highest power output achieved during the test was recorded and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Post-Exercise Blood Lactate Concentration
Lasso di tempo: At rest before exercise and at 3, 10, and 20 minutes post-exercise, following each supplementation period

Capillary blood lactate concentration (mmol/L) was measured using a portable lactate analyzer (Lactate Scout Sport) at rest and at 3, 10, and 20 minutes after the 30-second Wingate Anaerobic Test. Blood lactate concentrations were compared between the Rhodiola rosea and placebo conditions at each measurement time point.

At rest before exercise and at 3, 10, and 20 minutes post-exercise, following each supplementation period

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Relative Peak Power During the 30-Second Wingate Anaerobic Test
Lasso di tempo: During the 30-second Wingate test at the end of each 4-day supplementation period

Relative peak power (W/kg) was calculated by normalizing the highest power output achieved during the 30-second Wingate Anaerobic Test to the subject's body mass. Values were compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Mean Power During the 30-Second Wingate Anaerobic Test
Lasso di tempo: During the 30-second Wingate test at the end of each 4-day supplementation period

Mean power (W) was determined as the average mechanical power output generated throughout the 30-second Wingate Anaerobic Test. Values were obtained from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Total Work During the 30-Second Wingate Anaerobic Test
Lasso di tempo: During the 30-second Wingate test at the end of each 4-day supplementation period

Total work (kJ) was determined as the cumulative mechanical work performed throughout the 30-second Wingate Anaerobic Test. Values were derived from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Cadence at Peak Power During the 30-Second Wingate Anaerobic Test
Lasso di tempo: During the 30-second Wingate test at the end of each 4-day supplementation period

Cadence at peak power (rpm) was recorded as the pedaling rate corresponding to the highest power output achieved during the 30-second Wingate Anaerobic Test. Values were obtained from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Rate of Fatigue During the 30-Second Wingate Anaerobic Test
Lasso di tempo: During the 30-second Wingate test at the end of each 4-day supplementation period

Rate of fatigue (%) was obtained from the cycle ergometer software as an indicator of the relative decline in power output during the 30-second Wingate Anaerobic Test. Values were compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Yücel Makaracı, PhD, Karamanoğlu Mehmetbey University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 maggio 2026

Completamento primario (Effettivo)

15 maggio 2026

Completamento dello studio (Effettivo)

15 maggio 2026

Date di iscrizione allo studio

Primo inviato

9 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

9 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • KMU-09-2025/153
  • 15-YL-25 (Altro numero di sovvenzione/finanziamento: Karamanoğlu Mehmetbey University (KMU) Scientific 645 Research Projects (BAP) Unit)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data may be made available from the corresponding author upon reasonable request. Data will not be publicly accessible due to participant privacy considerations. Each request will be evaluated individually based on its scientific purpose, ethical considerations, and applicable data protection requirements. Data sharing will be subject to appropriate safeguards to protect participant confidentiality.

Periodo di condivisione IPD

Following publication of the study results, upon reasonable request.

Criteri di accesso alla condivisione IPD

Qualified researchers may request access to de-identified individual participant data by contacting the corresponding author. Each request will be evaluated individually based on its scientific purpose, methodological justification, and compliance with applicable ethical and data protection requirements. Data may be shared upon reasonable request, provided that participant confidentiality and privacy are adequately protected.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .